Vinay Hosmane, MD
Cardiovascular Disease · Wilmington, DENPI 1326018631
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Johnson & Johnson accounts for 95.4% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2024 at $61,650 and has fallen 99.1% since, to $551 in 2025. Among cardiovascular disease clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 387 payments — averaging $661.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$244K
- Novartis$10K
- Janssen Scientific Affairs, LLC$327
- AstraZeneca$297
- Pfizer$216
- Biotronik Inc.$203
- plus $1K from 15 others
What the payments were for
- Consulting fees$108,60842%
- Speaking & faculty fees$136,08953%
- Travel & lodging$3,7571%
- Food & beverage$7,4183%
- Education$530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 285 | $244,255 |
| Novartis | 47 | $9,601 |
| Janssen Scientific Affairs, LLC | 7 | $327 |
| AstraZeneca | 11 | $297 |
| Pfizer | 5 | $216 |
| Biotronik Inc. | 5 | $203 |
| Abbott | 4 | $196 |
| Medtronic | 3 | $193 |
| Cvrx, Inc. | 1 | $153 |
| Amgen | 1 | $88 |
| Merck | 5 | $83 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $66 |
| Inspire Medical Systems, Inc. | 1 | $57 |
| Irhythm Technologies, Inc. | 1 | $50 |
| GE HealthCare | 1 | $45 |
| Heartflow, Inc. | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Boston Scientific | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $11 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$240,374
- ENTRESTO$8,960
- Barostim Neo System$153
- VANTA ADAPTIVESTIM$147
- VYNDAQEL$120
How this compares
$255,925 in reported general payments places this provider in the 95th percentile of 104 cardiovascular disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 443 | $588,562 |
| EntrestoSacubitril/Valsartan | 87 | $143,583 |
| EliquisApixaban | 40 | $54,252 |
| FarxigaDapagliflozin Propanediol | 30 | $46,632 |
| Rosuvastatin Calcium | 655 | $15,473 |
| DapagliflozinDapagliflozin Propanediol | 11 | $6,296 |
| Valsartan | 152 | $5,891 |
| Ezetimibe | 155 | $5,379 |
| Metoprolol Succinate | 279 | $3,592 |
| Atorvastatin Calcium | 232 | $3,358 |
| Amlodipine Besylate | 282 | $2,443 |
| Hydralazine Hcl | 157 | $2,371 |
| VascepaIcosapent Ethyl | 12 | $2,300 |
| Midodrine Hcl | 38 | $2,265 |
| Carvedilol | 219 | $2,054 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $244,255 | $588,562443 claims |
| NovartisEntresto | $9,601 | $143,58387 claims |
| PfizerEliquis | $216 | $54,25240 claims |
| AstraZenecaFarxiga | $297 | $46,63230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 104 cardiovascular disease providers in Delaware.
Other cardiovascular disease in Wilmington
- Hamid DeliriWilmington$10K
- Piamsook AngkeowWilmington$4K
- Andra PopescuWilmington$3K
- Yolanda HendleyWilmington$3K
- Vincent MarmoWilmington$2K
- George DavisWilmington$2K
- Wasif QureshiBear$122K
- Rajinder PrasadLewes$72K
- Ehtasham QureshiLewes$52K
- Edward GoldenbergNewark$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.